Ejung Moon is a Group Leader in Radiation Biology and the Tumour Microenvironment at the Department of Oncology, University of Oxford's Medical Sciences Division. Her research focuses on hypoxia-driven tumor progression and radiation response mechanisms. Education: PhD in Pharmacology and Cancer Biology from Duke University Training: Postdoctoral work with Amato Giaccia at Stanford University Research Interests: Elucidating how hypoxia-induced MAFF protein regulates tumor cell invasion, metastasis, and radiation resistance through antioxidant response pathways. Current work explores MAFF dimerization dynamics and metabolic reprogramming in hypoxic tumors. Scientific Contributions: Identified MAFF's role in radiation-induced antioxidant gene regulation (2021, Nature Communications ). Recent studies investigate iron metabolism's impact on FLASH radiotherapy effects. Scientific Awards: Breast Cancer Research Program (BCRP) predoctoral fellowship Laboratory & Collaborations: Moon Lab collaborates with Oxford Cancer and NHS Cancer and Haematology Centre. Key partnerships include Stanford University's radiobiology research groups.
Swiss Federal Institute of Technology in LausanneSwitzerland
Pascal Frossard is a Full Professor at the Department of Electrical Engineering in the School of Engineering (STI) at EPFL, with a courtesy appointment in the School of Computer and Communication Sciences. He founded and directs the LTS4 laboratory since 2003, co-leads the EPFL AI Center and Swiss Data Science Center, and serves as Associate Dean for Research at STI. Research Focus: Machine Learning, Graph Signal Processing, AI Applications in Healthcare, Computer Vision Academic Leadership: IEEE Fellow, ELLIS Fellow, Conference Chair roles Key Projects: Digital Pathology for Oncology, Cardiac Digital Twins, Robust Machine Learning Research Interests: His work bridges signal processing, machine learning, and applied mathematics, emphasizing biomedical applications. Recent research includes adversarial robustness in classifiers, network representation learning, and 360-degree video analysis. Scientific Awards: IEEE Fellow ELLIS Fellow Leadership in IEEE technical committees Advising & Grants: Supervised 20+ PhD students and postdocs. Secured major grants from PHRT, Hasler Foundation, FNS-Sinergia, Armasuisse, Google, and Cisco.
Professor Thomas Bein is affiliated with the Department of Chemistry at Ludwig-Maximilians-Universität München (LMU) , where he leads the Functional Nanosystems research group. His work focuses on synthesizing and characterizing nanostructured materials with applications in energy, catalysis, and biomedical delivery. Mesoporous nanoparticles for drug delivery Semiconductor nano-morphologies for photovoltaics Photoelectrochemical water splitting Metal-organic frameworks (MOFs) Electroactive networks His research emphasizes atomic-scale control of material architectures using self-assembly, hydrogen bonding, and covalent interactions, enabling precise tuning of electronic, optical, and catalytic properties. A review of his recent publications reveals cutting-edge investigations into covalent organic frameworks (COFs), perovskite-inspired solar materials, and functional nanoparticle systems. Key trends include optimizing energy conversion efficiency, enhancing stability in optoelectronic devices, and exploring bio-compatible nanocarriers for targeted therapies. Professor Bein’s group actively contributes to interdisciplinary projects at the intersection of chemistry, physics, and biomedical engineering, with ongoing collaborations in solar energy, sustainable materials, and nanomedicine.
Harris H. Wang is an Associate Professor in the Department of Systems Biology and Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons, where he also serves as Interim Chair of Systems Biology. He is affiliated with the Center for Computational Biology and Bioinformatics (C2B2) and the Integrated Program in Cellular, Molecular and Biomedical Studies (CMBS). B.S., Physics and Mathematics, MIT Ph.D., Biophysics, Harvard University Dr. Wang's research lies at the intersection of systems and synthetic biology, focusing on developing foundational technologies for genome engineering, microbiome manipulation, and synthetic genomics. His lab pioneers methods such as MAGE, MAGIC, CAST, and CAMII to enable high-throughput genetic manipulation, in situ microbiome engineering, and AI-driven microbial culturomics. Key research themes include understanding microbial community dynamics, engineering cellular memory systems, designing biocontained genetic circuits, and applying synthetic biology to human health challenges in personalized medicine and infectious disease. His recent publications reveal a strong trend in spatial and functional metagenomics, CRISPR-based microbiome editing, and synthetic biology tools for data storage and genetic stability. The articles span high-impact journals like Nature , Science , and Nature Biotechnology , reflecting his leadership in developing scalable, programmable biological systems. Scientific Awards: NIH Director’s Early Independence Award Forbes 30 Under 30 in Science Sloan Research Fellowship NSF CAREER Award ONR Young Investigator Award Burroughs Wellcome Fund PATH Award Schaefer Scholar Blavatnik National Award Vilcek Prize PECASE Dr. Wang has advised numerous PhD and postdoctoral researchers, many of whom have gone on to independent scientific careers. His lab is supported by major grants from NIH, NSF, DARPA, DOE, and foundations including the Bill & Melinda Gates Foundation and CZ Biohub NY. He is actively involved in educational initiatives, including organizing Columbia’s iGEM team and the Cold Spring Harbor Laboratory Synthetic Biology course. The Wang Lab is based at the Columbia University Irving Medical Center and is part of national consortia such as the Engineering Biology Research Consortium (EBRC) and the Genome Project-Write (GP-Write) initiative. The lab develops and applies cutting-edge technologies in automation, machine learning, and synthetic biology to engineer microbiomes for applications in medicine, global health, and climate change.
Hauke Smidt is a Personal Professor at Wageningen University & Research, affiliated with the Molecular Ecology group within the Faculty of Veterinary Medicine and Animal Sciences. His research focuses on microbial ecology, particularly gut microbiota dynamics, antibiotic resistance, environmental microbiology, and the One Health framework. Smidt has supervised over 50 PhD students and contributed to 519 publications, including studies on microbiome resilience, fermented food impacts, and bioremediation strategies. Education and affiliations include leadership roles in projects addressing antimicrobial resistance, pig health, and drinking water microbiology. His work spans collaborations across Europe and Asia, with notable contributions to understanding microbial community responses to environmental stressors and dietary interventions. Smidt is actively involved in public outreach, as seen in media contributions discussing microbiome research and health benefits. Key projects include aquifer treatment for drinking water, microbiome simulation models, and combating plant pathogens. His awards and recognition are not explicitly listed, but his extensive publication record and project leadership highlight significant academic impact.
Dr. Keith Alexander Sharkey is a Professor in the Department of Physiology and Pharmacology at the Cumming School of Medicine, University of Calgary. He is also a Full Member of both the Hotchkiss Brain Institute and The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases. Dr. Sharkey has been at the University of Calgary since his appointment as Assistant Professor in 1990, dedicating his career to understanding the neural control of the gastrointestinal tract. From 2005-2021, he held the Crohn's and Colitis Canada Chair in Inflammatory Bowel Disease Research, demonstrating his longstanding commitment to advancing knowledge in gastrointestinal sciences. Dr. Sharkey's educational journey began with a BSc (Hons) in Nutrition from the University of London in 1981, followed by a PhD in Physiology from the University of Liverpool in 1985. After completing postdoctoral training in Hungary, the UK, and Canada, he joined the University of Calgary faculty in 1990, where he has remained throughout his distinguished academic career. Dr. Sharkey's research program centers on understanding the physiology and pathophysiology of the neural control of the gastrointestinal tract and brain-gut interactions in health and disease. His laboratory investigates two main areas: the role of the endocannabinoid system in regulating GI motility and intestinal barrier function, and the physiology of the enteric nervous system in controlling motility and barrier function. His work employs state-of-the-art approaches including live cell imaging and molecular genetics. Recent publications show his expanding interest in connections between gut function and neurodegenerative conditions like ALS, with multiple 2024-2025 papers examining sexual dimorphism in disease processes and gut-brain axis mechanisms. Fellow, Royal Society of Canada (2024) Cumming School of Medicine's van de Sande Distinguished Achievement Award for Mentorship (2021) Distinguished Research Award, American Physiological Society (2021) Finkelstein Award for Excellence, Crohn's and Colitis Canada (2016) Fellow, Canadian Academy of Health Sciences (2015) Fellow, Canadian Association of Gastroenterology (2015) Killam Annual Professor Award, University of Calgary (2013) Dr. Sharkey has mentored numerous students throughout his career, as evidenced by his 2021 Mentorship Award. His research is supported by significant funding, including a CIHR Foundation grant exploring how enteric nerves and glia maintain intestinal homeostasis. He has also participated in university strategic initiatives focused on Brain and Mental Health (2015-2021) and Infections, Inflammations and Chronic Diseases (2015-2021), demonstrating his interdisciplinary approach. The Sharkey Lab provides a safe, inclusive, and diverse research environment that encourages open scientific exchange from diverse viewpoints. His laboratory is actively engaged in multiple collaborative projects, including investigations with UBC Okanagan on diet and probiotics targeting the gut-brain metabolic interactome, and with University of Calgary colleagues studying gut microbiota's role in ALS. Dr. Sharkey continues to advance our understanding of neural mechanisms controlling gastrointestinal function with upcoming courses scheduled for Fall 2024 and Winter 2025.
SUNY College of Environmental Science and ForestryUnited States
Jun Hyung Lee is a Visiting Assistant Professor in the Department of Environmental Biology at SUNY College of Environmental Science and Forestry (ESF). His research focuses on advancing forest tree improvement and conservation through molecular and synthetic biology approaches, with a particular emphasis on enhancing plant resilience to environmental stresses via beneficial microbial interactions. He teaches courses in plant biotechnology and tissue culture methods. Education includes a Ph.D. in Forest Genetics from Purdue University (USA), and M.S. and B.S. degrees in Plant Science from Seoul National University (South Korea). His work integrates cutting-edge genetic engineering techniques with ecological studies to address challenges in plant stress tolerance, symbiosis, and epigenetic regulation. Recent projects include identifying novel symbiosis pathways for thermotolerance and analyzing flooding tolerance in hybrid poplars. Publications highlight contributions to plant-microbe interaction research, synthetic biology applications, and genome editing epigenetic impacts. Collaborations span institutions like Oak Ridge National Laboratory and the University of Georgia, reflecting his transdisciplinary approach to plant science. Lee’s teaching emphasizes practical skills in biotechnology, bridging laboratory innovation with field applications.
University of Illinois Urbana-ChampaignUnited States
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.
Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
University of California, Los AngelesUnited States
Julienne Bower is a Professor at the University of California, Los Angeles (UCLA) with joint appointments in the Department of Psychology and the Department of Psychiatry/Biobehavioral Sciences. She serves as Director of the Mind-Body Research Lab, Associate Director of the Cousins Center for Psychoneuroimmunology, and as a Member of the Jonsson Comprehensive Cancer Center. Her research explores mind-body interactions in individuals facing stressful life events, particularly cancer patients and survivors, focusing on biological pathways linking psychological states to health outcomes and the effects of mind-body interventions. Ph.D. from UCLA Area Chair: Health Psychology Primary Area: Health Psychology Secondary Area: Clinical Psychology Location: 6538 Pritzker Hall, UCLA Dr. Bower's research examines how positive psychological factors (e.g., benefit finding, positive affect) influence physical health through immune and neuroendocrine pathways, while also investigating mind-body interventions like yoga and mindfulness meditation. Her work spans observational, experimental, and intervention studies, emphasizing the immune system as a central mechanism. The Mind-Body Research Lab, under Dr. Bower's leadership, has published extensively on topics including cancer-related fatigue, stress-induced inflammation, and the physiological impacts of psychosocial interventions. Key publications address NF-κB signaling, glucocorticoid resistance, and cortisol dysregulation in cancer survivors. Dr. Bower's lab is actively recruiting graduate students for 2024 through the UCLA Health Psychology Program, offering training in psychoneuroimmunology, cancer prevention, and mind-body research methodologies.
Associate Professor Adam Irwin is an NHMRC Emerging Leadership Fellow and Associate Professor in Infectious Diseases at the University of Queensland (UQ) and Queensland Children’s Hospital. He holds positions within the UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences. His work focuses on early sepsis recognition, antimicrobial stewardship, and pediatric infectious diseases. Dr. Irwin completed his medical degree at the University of Birmingham and his PhD in 2016 from the University of Liverpool’s Institute of Infection and Global Health. He has led initiatives like the Queensland Paediatric Sepsis Program, recognized with a Global Sepsis Alliance Award and Queensland Health Excellence Awards. His research spans sepsis pathway implementation, antimicrobial resistance trends, and rapid diagnostic tools. Notable grants include NHMRC funding for studies on multi-drug resistant infections and Children’s Hospital Foundation support for genomics and antimicrobial stewardship projects. He supervises PhD candidates in areas like bloodstream infections and molecular diagnostics. Dr. Irwin collaborates across institutions, contributing to projects such as the RAPIDS Study Group and the PAEDS surveillance network. Awards include the NHMRC Emerging Leadership Fellowship and recognition for sepsis program excellence. His work emphasizes translating research into clinical practice, improving outcomes for critically ill children through evidence-based protocols and innovative diagnostics.
Swiss Federal Institute of Technology in LausanneSwitzerland
Pierre Vandergheynst is a Full Professor at the Swiss Federal Institute of Technology Lausanne (EPFL) in the Department of Electrical Engineering, with a courtesy appointment in Computer and Communication Sciences. He serves as EPFL’s Vice-Provost for Education since 2015 and leads the Signal Processing Laboratory 2 (LTS2). His research spans harmonic analysis, sparse approximations, mathematical data processing, and applications in signal/image processing, computer vision, machine learning, and graph-based data analysis. PhD in Mathematical Physics (1998), Université catholique de Louvain Postdoctoral Researcher at EPFL (1998-2001) Assistant Professor at EPFL (2002-2007) His research explores geometry/symmetry in high-dimensional data, redundant dictionaries for dimensionality reduction, and computational harmonic analysis on manifolds. Recent work focuses on protein structure modeling, geometric deep learning, and graph-based signal processing. Key article trends include graph neural networks for protein analysis, geometric deep learning in neuroscience, and structured knowledge priors in neural models. His 2023-2025 publications emphasize interpretable AI, long-range dependencies in graphs, and molecular representation learning. Scientific Awards: IEEE Signal Processing Magazine Best Paper Award (2023) Signal Processing Society Best Paper Award (2022) Apple ARTS Award (2007) De Boelpaepe Prize, Royal Academy of Sciences of Belgium (2009-2010) He has supervised over 30 PhD theses and contributed to foundational work in graph signal processing, compressive sensing, and geometric deep learning. His lab develops tools for data science on non-Euclidean structures, with applications in medicine, astronomy, and wireless systems.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.
